Valneva and Pfizer tout results for the PhII of its Lyme disease vaccine
Pfizer and Valneva are touting positive results in a Phase II trial for their Lyme disease vaccine candidate when it was administered as a booster.
The trial showed VLA15 had favorable seroconversion rates, or SCRs, for all outer surface protein A (OspA) serotypes, in all of the age groups tested. The dosing schedule of zero to two months and then two to six months reported an SCR of 95.3%, while the dosing regimen of zero to six months had an SCR of 94.6%.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
